PREVENT HPV Cancers Act of 2025
- Sponsor
- Rep. Castor, Kathy [D-FL-14]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Dec 10, 2025
Bottom line
The PREVENT HPV Cancers Act aims to boost HPV vaccination and cancer screening through targeted public health campaigns and increased funding for early detection programs to reduce HPV-associated cancers and address health disparities.
What it actually does
This bill establishes a national public awareness campaign led by the Centers for Disease Control and Prevention (CDC) to increase human papillomavirus (HPV) vaccination rates and combat misinformation. It mandates the development of culturally and linguistically competent resources tailored for various communities, including those with high rates of unvaccinated individuals, specific racial/ethnic groups, and rural areas. Additionally, it reauthorizes and increases funding for the National Breast and Cervical Cancer Early Detection Program.
Proponents argue
Proponents argue that the bill addresses critical public health needs by increasing awareness of HPV vaccination as a proven cancer prevention tool and improving access to life-saving cancer screenings. They highlight the significant disparities in HPV-associated cancer rates among certain communities and emphasize the importance of evidence-based campaigns to combat misinformation and improve vaccination rates, especially among adolescents and underserved populations.
Opponents contend
Potential opponents might raise concerns about the overall cost of the public awareness campaign or question the effectiveness of such campaigns in significantly changing public health behaviors. Some may also express skepticism about government involvement in health education or raise issues related to vaccine promotion, although this bill focuses on education and does not mandate vaccination. Others might argue that resources could be better allocated to alternative public health initiatives.
The bill is concise and easily digestible, allowing for a quick and informed evaluation by any interested reader.
Section 3(a), amending Section 317 of the Public Health Service Act (42 U.S.C. 247b) by adding subsection (o).
Establishment of National HPV Cancer Prevention Public Awareness Campaign
This provision directs the Secretary of Health and Human Services, through the CDC, to launch a national campaign. The campaign's goals are to raise awareness about HPV vaccination for cancer prevention, counter misinformation, and increase vaccination rates. It requires consultation with various stakeholders, including medical professionals, public health associations, and community organizations, to ensure the campaign is evidence-based and culturally appropriate.
Supporters argue
Supporters argue this campaign is crucial for closing the gap in HPV vaccination rates, which are lower than other recommended adolescent vaccines. They emphasize the importance of combating misinformation and tailoring messages to specific communities to address health disparities and prevent thousands of cancer cases annually.
Critics contend
Some critics might argue that public awareness campaigns can be costly with uncertain returns on investment, or that the government should not be involved in promoting specific medical interventions. Others might express concerns about the content of the campaign, particularly regarding vaccine safety messaging, or the potential for overreach in public health communication.
Tradeoffs
The bill balances the need for broad public health messaging with the necessity of culturally and linguistically tailored approaches to reach diverse communities effectively. It also navigates the tension between promoting vaccination and respecting individual health choices, aiming to inform rather than coerce.
Section 3(a), amending Section 317(o)(3) of the Public Health Service Act.
Campaign Design and Implementation Requirements
This section outlines specific mandates for the public awareness campaign. It requires the use of evidence-based media, competitive grants for nonprofit entities to run the campaign, and the development of culturally and linguistically competent resources for specific communities (e.g., unvaccinated individuals, Black and Hispanic women, rural areas, active-duty service members and veterans). It also mandates dissemination of information to healthcare providers and schools, coordination with other federal efforts, message testing, and grants to state, local, and Tribal public health departments for local engagement and resource dissemination.
Section 3(a), amending Section 317(o)(5) of the Public Health Service Act.
Funding for HPV Cancer Prevention Public Awareness Campaign
This provision authorizes an appropriation of $5,000,000 for each of fiscal years 2026 through 2030 to carry out the national HPV cancer prevention public awareness campaign. This sets the financial framework for the campaign's operations over a five-year period.
Section 3(b)
Congressional Report on Campaign Assessment
This section requires the Secretary of Health and Human Services to submit a report to Congress by September 30, 2027. The report must include a qualitative assessment of the HPV awareness campaign and its activities, as well as an analysis of its impact on HPV-associated cancers. This ensures accountability and allows Congress to evaluate the campaign's effectiveness.
Section 4(a), amending Section 1510(a) of the Public Health Service Act (42 U.S.C. 300n-5(a)).
Increased Authorization for National Breast and Cervical Cancer Early Detection Program
This provision reauthorizes and increases the appropriation for the National Breast and Cervical Cancer Early Detection Program. It amends existing law to authorize $300,000,000 for each of fiscal years 2026 through 2030, up from the previous authorization of $275,000,000 for fiscal year 2012. This provides a significant boost in funding for a critical cancer screening program.
Section 4(b), amending Section 1501(d) of the Public Health Service Act (42 U.S.C. 300k(d)).
Extension of Coordinating Committee for Breast and Cervical Cancer Early Detection
This provision extends the authorization for the coordinating committee related to the Breast and Cervical Cancer Early Detection Program from 2020 to 2030. This ensures that the committee, which plays a role in guiding the program, can continue its work in alignment with the reauthorized funding period.
Extends the authorization for the coordinating committee for the Breast and Cervical Cancer Early Detection Program from 2020 to 2030.
Section 4(b), amending Section 1501(d) of the Public Health Service Act.
Why it matters:This is standard legislative practice for updating statutory dates to align with program reauthorizations, not necessarily evasive.
Case for: Supporters would argue it ensures continuity and effective governance for a vital cancer screening program, allowing the coordinating committee to continue its work without interruption.
Case against: No specific opposition is typically raised against such technical extensions, as they are administrative in nature and support an established public health program.
Estimated impact: Administrative impact, ensuring continued coordination for a program with $300 million annual authorization.
Requires the HPV awareness campaign to develop culturally and linguistically competent resources tailored for "populations impacted by the increase in oropharynx cancers, including active-duty service members and veterans."
Section 3(a), (o)(3)(C)(i)(III)
Why it matters:This is likely standard legislative practice to ensure specific, high-risk populations are explicitly addressed within a broad public health initiative, rather than an attempt to hide it.
Case for: Proponents would highlight this as a critical recognition of a specific population facing increased risk of oropharynx cancers, ensuring that targeted, effective prevention messages reach those who serve and have served the country.
Case against: No specific opposition is typically raised against including specific vulnerable populations in public health campaigns.
Estimated impact: Potentially significant health benefits for a specific, often overlooked, high-risk demographic within the broader population.